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Abstract: Aims
To compare non-fatal cardiovascular (CV) events and metabolic outcomes, among
obese patients with insulin-treated type 2 diabetes who underwent bariatric surgery
compared to a propensity matched non-bariatric cohort.
Methods
A retrospective cohort study was conducted among 11,125 active patients with type 2
diabetes from The Health Improvement Network (THIN) database. Propensity score
matching (1:6 ratio) was used to identify patients who underwent bariatric surgery
(N=131) with a non-bariatric cohort (N=579). Follow-up was undertaken for 10 years
(9,686 person-years) to compare differences in metabolic outcomes and CV risk
events that included: Acute Myocardial Infarction (AMI), stroke, Coronary Heart
Disease (CHD), Heart Failure (HF) and Peripheral Artery Disease (PAD). Cox
proportional regression was used to compute the outcomes between groups.
Results
Mean age was 52±13 years (60% female); baseline weight and BMI were 116±25kg
and 41±9kg/m2, respectively. Significant reductions in weight and BMI were observed
in bariatric and non-bariatric cohorts during 10 years of follow-up. Bariatric surgery had
a significant cardio-protective effect by reducing the risk of non-fatal CHD (adjusted
hazard ratio [aHR]: 0.29, 95%CI:0.16–0.52, p<0.001) and PAD events (aHR: 0.31;
95%CI:0.11–0.89; p=0.03). However, surgery had no significant effect on AMI
(aHR:0.98, p=0.95), stroke (HR:0.87, p=0.76) and HF (HR:0.89, p=0.73) risks. Bariatric
surgery had favourable effects on insulin-independence, HbA1c and BP.
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Conclusion
Among obese insulin-treated patients with type 2 diabetes, bariatric surgery is
associated with significant reductions in non-fatal CHD and PAD events, lower body
weight, BP, and a greater likelihood of insulin independence during 10 years of follow-
up.
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Abstract 
 
Aims: To compare non-fatal cardiovascular (CV) events and metabolic outcomes, among 
obese patients with insulin-treated type 2 diabetes who underwent bariatric surgery 
compared to a propensity matched non-bariatric cohort. 
Methods: A retrospective cohort study was conducted among 11,125 active patients with 
type 2 diabetes from The Health Improvement Network (THIN) database. Propensity score 
matching (1:6 ratio) was used to identify patients who underwent bariatric surgery (N=131) 
with a non-bariatric cohort (N=579).  Follow-up was undertaken for 10 years (9,686 person-
years) to compare differences in metabolic outcomes and CV risk events that included: 
Acute Myocardial Infarction (AMI), stroke, Coronary Heart Disease (CHD), Heart Failure (HF) 
and Peripheral Artery Disease (PAD). Cox proportional regression was used to compute the 
outcomes between groups. 
Results: Mean age was 52±13 years (60% female); baseline weight and BMI were 116±25kg 
and 41±9kg/m2, respectively. Significant reductions in weight and BMI were observed in 
bariatric and non-bariatric cohorts during 10 years of follow-up. Bariatric surgery had a 
significant cardio-protective effect by reducing the risk of non-fatal CHD (adjusted hazard 
ratio [aHR]: 0.29, 95%CI:0.16–0.52, p<0.001) and PAD events (aHR: 0.31; 95%CI:0.11–0.89; 
p=0.03). However, surgery had no significant effect on AMI (aHR:0.98, p=0.95), stroke 
(HR:0.87, p=0.76) and HF (HR:0.89, p=0.73) risks. Bariatric surgery had favourable effects on 
insulin-independence, HbA1c and BP. 
Conclusion: Among obese insulin-treated patients with type 2 diabetes, bariatric surgery is 
associated with significant reductions in non-fatal CHD and PAD events, lower body weight, 
BP, and a greater likelihood of insulin independence during 10 years of follow-up. 
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What is already known about this subject? 
- Obesity and type 2 diabetes are associated with high risk of cardiovascular events 
- Obesity is causally associated with peripheral artery disease 
- Insulin –treated type 2 diabetes is associated with additional excess risk of 
cardiovascular events 
- Bariatric surgery in people with or without diabetes reduces cardiovascular events 
 
What does this study add? 
- This study focuses on insulin treated type 2 diabetes – recently recognised to be 
associated with higher risks of cardiovascular events 
- Among insulin treated type 2 diabetes, bariatric surgery is associated with significant 
reduction in non-fatal coronary heart disease and peripheral artery disease 
- Among insulin treated type 2 diabetes, bariatric surgery is associated with significant 
reduction and maintenance of weight loss, significant reduction in HbA1c, with 
relapse of HbA1c levels after 6 years of follow up and significant increase of insulin 
independence 
-  
How might this impact on clinical practice? 
- Bariatric surgery should be considered as a genuine therapeutic option for the 
management of obese insulin treated type 2 diabetes to reduce coronary heart 
disease, peripheral artery disease events, reduce HbA1c levels and potentially 
reduce long-term risk of microvascular complications of diabetes as well as inducing 
insulin indepence. 
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Background 
Obesity and Type 2 diabetes (T2D) are major global health problems that are intrinsically 
linked with adverse cardiovascular (CV) outcomes1,2. Obesity-associated coronary artery 
disease and myocardial dysfunction have been shown to be a direct consequence of excess 
dysfunctional adipose tissue, driven by increased pro-inflammatory state, insulin resistance, 
endothelial dysfunction and the development of myocardial hypertrophy3. Consequently, 
weight loss by any means has been shown to improve CV outcomes4. Although diet and 
exercise play a crucial role in obesity management, lifestyle alone may not achieve durable 
weight loss in the majority of patients5. Bariatric surgery therefore has emerged as the most 
effective and durable strategy for long-term weight loss in morbidly obese individuals6. The 
two most commonly performed bariatric surgical procedures are the Roux-en-Y gastric bypass 
(RYGB) and sleeve gastrectomy (SG). Indeed, previous studies have shown beneficial effects 
of these bariatric surgical procedures on CV outcomes7-9.  
 
Many patients with T2D will require insulin treatment to manage hyperglycaemia, to reduce 
the risk of long-term vascular complications10. However, insulin therapy is known to induce 
~4-9 kg weight gain in the first year of treatment, while escalation of insulin treatment doses 
are associated with greater weight gain11 and excess CV risk12.  Furthermore, evidence from 
randomized controlled trial and observational studies have implicated insulin therapy in 
patients with T2D with increased CV risk and mortality13-16, possibly due to weight gain, 
recurrent hypoglycaemia and iatrogenic hyperinsulinemia17,18. Thus, a cohort of insulin-
treated patients with T2D, represent a complex heterogenous, challenging group of patients, 
many of whom have significant comorbidities and high CV disease risk. No studies have 
assessed the effect bariatric surgery on cardiovascular outcomes among insulin-treated 
patients with T2D in routine clinical care. 
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Methods 
Study design, data sources and study population 
This was a retrospective cohort study that used The Health Improvement Network (THIN), an 
anonymised health care records derived from over 600 UK general practices, containing 
details on demographics, lifestyle characteristics, major medical and surgical conditions, drug 
utilisation, and health outcomes of over 17 million patients, 3.1 million of which are active 
patients19. Our dataset contains all adult patients (age >18 years) with T2D and have been 
prescribed with any form of insulin therapy up to September 2017 (N=11,125). Patients’ index 
date was either the day of bariatric surgery (RYGB or SG) or, in case they have not received 
bariatric surgery, first intensification of insulin therapy. We excluded patients with type 1 
diabetes or non- insulin-treated T2D. Ethics approval was provided by the NHS South East 
Multi-centre Research Ethics Committee (MREC). 
 
Exposure and outcomes 
Exposure of interest is bariatric surgery (RYGB or SG). Patients were censored throughout 10 
years of follow-up – following the development of primary outcome, transferred out, loss to 
follow-up or at the end of the study. Primary outcome was patients’ survivability against non-
fatal CV events with further stratification to include CV events into divisions of time to the risk 
of Acute Myocardial Infarction (AMI), stroke, Coronary Heart Disease (CHD), Heart Failure (HF) 
and Peripheral Artery Disease (PAD). Secondary outcomes included health covariates such as 
body weight, calculated BMI, HbA1c, total cholesterol, systolic/diastolic blood pressure and 
insulin independence.  
 
Covariates and follow-up strategy 
We followed-up the treatment group whom underwent bariatric surgery and compared with 
their propensity-matched (PS) matched non-bariatric surgery from their first insulin 
prescription date up to the endpoint of 10-year of follow-up. Patients with CV events prior to 
the designated baseline point were excluded from the primary survival estimation on each 
stratified CV element. Baseline clinical parameters (average values from multiple entries) 
were measured at the same time window according to patient’s treatment category, i.e. 90 
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days up to one day before the surgery date or first intensification of insulin therapy. 
Covariates were, then, recalculated at 6-month, and at each year point up to 10 years of 
follow-up; with 90 days window on every concurring point of time. 
 
Statistical analysis 
Primary analysis was time to the risk of stratified non-fatal CV events that included AMI, 
stroke, CHD, HF and PAD in a PS-matched groups. The PS model was estimated by using 
logistic regression model to adjust for baseline characteristics, thus, minimising allocation bias 
between groups. The balance assessment was made between bariatric (treated) and non-
bariatric (untreated) groups by measuring standardised differences before and after the 
matching procedure. The mean form continuous covariates and proportion of categorical 
variables between groups were examined and summarised. Each treatment subject was 
matched to six reference subjects at the nearest distance measured by the estimated PS, 
based on the estimated treatment probabilities20. We employed caliper width=0.05 of the 
standard deviation of the logit of the PS to minimise distance within matched sets which may 
improve match quality but would limit excessive number of matched subjects21. A caliper 
width of <0.2 has been shown to result in optimal estimation compared to higher choices of 
caliper use22. PS was included in all Cox proportional hazards regression modelling as it was 
considered a prognostic covariate. Stratified log-rank test, with Kaplan-Meier survival curves 
respectively was used to compare the equality between the PS-matched groups. The absolute 
reduction in the probability of an event occurring within 10-year follow-up was calculated. 
Marginal hazard ratios were estimated to quantify the adjusted hazard of an event occurred 
in the bariatric group compared to the matched non-bariatric group. Proportional hazards 
assumptions were confirmed through Schoenfeld residuals test. Point estimates with 95% 
Confidence Intervals (CIs) at the conventional statistical significance level of 0.05 were used 
in the regression models. The proportional hazards assumption was examined by comparing 
the cumulative hazard plots grouped on exposure; no violations were observed. 
 
Missing data among covariates were managed through multiple imputations using the 
predictive means matching for continuous covariates with accounting to exposure (i.e. 
bariatric), age, gender, diabetes duration, Townsend deprivation status, marital status, 
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smoking and alcohol use23. To test the adequacy of our multiple imputation approach in 
addressing the impact of some missing data, we conducted a sensitivity analysis wherein the 
primary endpoints in the imputed dataset and were compared with the dataset with missing 
values and found to be similar, thereby affirming the robustness of the imputation method 
employed before PS matching procedure was performed24.  
 
We used Student’s t-test to estimate the mean changes in continuous variables (e.g. body 
weight & HbA1c) in both PS matched groups throughout 10-year of follow-up compared to 
their baseline measurements; and Pearson X2 to test on the likelihood of being off insulin at 
5 and 10 years from the baseline. Statistical significance was put at a p level of 0.05. To avoid 
the probability of type II error, the study was powered to 0.8 and the matched sample size of 
710 was found to detect a true difference of less than 0.1 between the two groups at 5% 
significance level. The study fulfilled the STROBE criteria for reporting observational studies. 
Throughout, we used SAS Software version 9.4 in the initial dataset management (SAS 
Institute, Cary, NC); Stata Statistical Software version 15.1 in all carried analysis (StataCorp., 
College Station, TX); and GraphPad/Prism version 8.0 for visualisation (La Jolla, CA).  
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Results 
Patients’ characteristics and total follow-up 
From 11,125 patients with insulin-treated T2D, we identified 155 patients who have had 
bariatric surgical operation. The PS matching procedure allowed 131 bariatric patients to be 
matched with up to six control subjects. This yielded a total number of 710 PS-matched 
participants. The median treatment duration was 10.07 years (interquartile range (IQR): 6.11–
14.31 years). The median follow-up was 8.42 years (IQR: 2.92–14.58 years) representing a 
total follow-up period of 9,686 person-years.  
 
In the matched cohort, the overall mean of age was 51.7 (SD 12.5) years; 59.6% were females. 
The mean body weight, BMI and HbA1c level were 115.7 (SD 25.4) kg, 40.7 (SD 9.2) kg/m2 and 
71.2 (SD 18.1) mmol/mol, respectively. The baseline characteristics in both bariatric and non-
bariatric groups were compared between the full and matched cohort with their standardised 
differences shown in Table 1. 
 
Cardiovascular event rates 
The probability of survival for non-fatal CHD was significantly different between matched 
bariatric and non-bariatric groups at 1-year (98.0% vs 89.6%), 5-year (92.2% vs 67.6%) and 10-
year (88.2% vs 51.6%) of follow-up (log-rank test p < 0.001) (Fig. 1c). A total of 277 (18 vs 259) 
events were reported with a crude event rate of 52.4 (21.4 vs 58.2) per 1000 person-years 
(95% CI 46.6–58.9). The probability of survival for non-fatal PAD was also significantly 
different at 5-year (90.5% vs 78.8%) and 10-year (84.0% vs 53.1%) of follow-up (log-rank test 
p = 0.007) (Fig. 1e). A total of 59 (6 vs 53) events were observed with a crude event rate of 
62.1 (25.9 vs 73.8) per 1000 person-year (95% CI 48.1–80.2). The probabilities of survival for 
non-fatal AMI, stroke and HF were with little or no statistical significance between the 
matched groups throughout 10 years of follow-up (log-rank test p > 0.5) (Fig. 1a, 1b & 1d). 
Table 2 shows a summary of the events for each of the stratified CV components with 
absolute event rates.  
 
Risk of cardiovascular disease 
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Bariatric surgery was protective against all analysed CV elements in the matched cohort. The 
risk of non-fatal CHD and PAD in the bariatric group were significantly lower (by 71% & 69%, 
respectively) compared to the matched non-bariatric group (CHD aHR: 0.29, 95%CI 0.16–0.52, 
p < 0.001; PAD aHR: 0.31, 95%CI 0.11–0.89, p = 0.03) adjusted for age, HbA1c level, diabetes 
duration, oral antidiabetic drug use, diuretics use, antihypertensive drug use, Townsend 
deprivation status, alcohol use and smoking status. Despite protective tendency against non-
fatal AMI, stroke and HF, none of which was found with statistical significance (AMI aHR: 0.98, 
95%CI 0.54–1.77, p = 0.94; stroke aHR: 0.87, 95%CI 0.36–2.10, p = 0.75; HF aHR: 0.89, 95%CI 
0.47–1.70, p = 0.73) (Table 2).  
 
Changes in metabolic outcomes 
Significant reductions in the matched cohort (i.e. p < 0.001) favouring the bariatric group vs 
non-bariatric was observed in terms of body weight and BMI throughout all 10 years of follow-
up compared to baseline. Body weight and BMI for bariatric vs non-bariatric were: at 1-year 
point (97.5±24.2 vs 109.8±18.6 kg; 34.2±9.0 vs 38.8±7.4 kg/m2, respectively), at 5-year point 
(98.9±23.3 vs 107.1±18.2 kg; 34.8±9.2 vs 37.8±7.3 kg/m2, respectively), and at 10-year point 
(94.1±20.1 vs 107.6±17.3 kg; 32.9±7.7 vs 38.0±7.1 kg/m2, respectively) of follow-up (Fig. 2a & 
2b). The reduction in HbA1c was statistically significant up to six years of follow-up. At the 
first year the level of HbA1c in the bariatric vs non-bariatric (60.3±18.2 vs 72.0±17.9 
mmol/mol), at 3-year point (66.1±16.8 vs 71.3±17.8 mmol/mol) and at 6-year point 
(68.1±16.9 vs 72.8±18.8 mmol/mol). No statistical difference was observed beyond the 
seventh year in the HbA1c level between the matched groups (Fig. 2c). Total cholesterol was 
significantly reduced during the first six months of follow-up (4.12±0.99 vs 4.50±1.14 mmol/L, 
p = 0.008) (Fig. 2d). Blood pressure was also significantly reduced early following the bariatric 
surgery. The systolic blood pressure at 6-month point (130±18 vs 137±16 mmHg, p < 0.001) 
and at 1-year point (133±17 vs 137±15 mmHg, p = 0.07) (Fig. 2e). The diastolic blood pressure 
was significantly reduced in the bariatric vs non-bariatric (p < 0.05) up to two years of follow-
up (6-month: 76±10 vs 79±9; 1-year: 77±9 vs 79±9; 2-year: 76±10 vs 79±10 mmHg) (Fig. 2f). 
Figure 2 represents reduction in the matched cohort of the analysed outcome variables 
during 10 years of follow-up in comparison to their baseline measurements with 95% 
confidence intervals.  
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The analysis of the matched groups also revealed that, at one year of follow-up, 6.4% of whom 
underwent bariatric surgery were insulin independent compared to 7.9% non-bariatric with 
little or no statistical significance of a difference (X2=0.35, p = 0.55). At three years, 31.2% of 
bariatric patients were independent from insulin use compared to 17.6% non-bariatric 
(X2=10.59, p = 0.001). At six years, 41.5% of bariatric patients were independent from using 
insulin compared to 22.2% non-bariatric (X2=11.47, p = 0.001). At 10 years, 77.5% of bariatric 
patients were independent from using insulin compared to 33.7% non-bariatric (X2=28.71, p 
< 0.0001).   
 
Discussion  
This study showed that, among morbidly obese patients with insulin-treated T2D in routine 
clinical practice, bariatric surgery was associated with a significant 71% risk reduction in non-
fatal CHD and 69% reduction in PAD events, as well as significant reductions in weight, HbA1c, 
insulin independence and blood pressure. However, no significant reductions was observed 
with AMI, stroke and heart failure.    
 
Our findings were similar in pattern with previous observational studies on bariatric surgery 
with regards to cardiovascular and metabolic benefits7-9. Our study however focuses on 
patients with Insulin-treated T2D – known to be associated with higher risks of cardiovascular 
events13-16. Indeed, a previous study have shown that while bariatric surgery reduces 
cardiovascular events and mortality, the mortality risk in people with diabetes after bariatric 
surgery remains 35% higher than that of the general population.25  Our study therefore extends 
evidence of cardiovascular benefit of bariatric surgery in this patient cohort whose residual 
CV risk are likely to be higher.   Interestingly, a previous study in patients with diabetes reported a 
reduction in myocardial infarction but no effect was observed on stroke incidence8.  However, a 
factor–treatment interaction analysis showed that the effect of bariatric surgery on AMI was 
greater in participants with higher total cholesterol and triglyceride levels, implying that those 
with dyslipidemia were the ones who are likely to gain the most benefit. Since our PS-matched 
cohort have optimal mean LDL-cholesterol and triglyceride levels (~2.4 and 2.3 mmol/L), 
respectively due to high use of statin therapy, this may explain the lack of significant reduction 
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of AMI in our cohort while highlighting the importance of statin therapy in this patient cohort.  
Our observation of significant reduction in PAD events within this patient cohort is novel and 
have major clinical significant. A recent study have concluded that obesity is causally 
associated with PAD after controlling for potential confounders like hypertension, 
dyslipidemia and hyperglycemia26.  
 
Insulin therapy is known to induce weight gain11. Our data showed a major reduction in 
weight following bariatric surgery, which persisted at 10 years of follow up. While greater 
significant reduction in weight following bariatric surgery compared with control is 
anticipated, it is interesting to note that weight loss was also observed in our PS-matched 
control cohort. This is likely due to concurrent use of GLP-1 analogue in our patient cohort. 
Evidence of weight loss with GLP-1 as adjunct to insulin treatment has been shown in 
randomized controlled trials.27,28  In addition, we have also reported significant weight loss 
after 12 months of adding a GLP-1 to insulin therapy in routine clinical practice29. Of note, 
weight loss was not observed in our non- PS-matched control cohort, indicating robust PS 
matching protocol used in this study analysis (Supplement). The addition of GLP-1 therapy, in 
combination with use of other novel weight loss antidiabetic regimens like sodium glucose 
co-tranporter-2 (SGLT-2) inhibitor, as well as significant calorie restriction may also explain 
the smaller but appreciable percentage of patients who were insulin independence in the PS-
matched control cohort, compared with those who underwent bariatric surgery. 
Interestingly, in contrast to the observed weight loss which persisted over 10 years of follow-
up, the reduction in HbA1c was statistically significance only up to six years of follow-up post-
surgery, with a rise in HbA1c during further follow-up. Previous studies comparing bariatric 
surgery outcomes with medical/lifestyle intervention have mainly reported HbA1c reduction 
up to five years post surgery30-32, albeit in patients with T2D irrespective of treatment 
regimen. The discordance between long-term weight and HbA1c outcomes suggested that 
the observed relapse in HbA1c level was independent of weight regain.  Nonetheless, any 
beneficial effects of bariatric surgery on weight, HbA1c reduction and insulin independence 
will have significant impact on the long-term risk of vascular complications of diabetes and 
will likely confer cost savings to the UK National Health Service in the long-term.   
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The main strength of our study derives from the inclusion of a relatively large cohort of insulin-
treated T2D in a real-world population which can be generalized to the UK or similar 
population. This implies that our findings will be generalizable to various population with 
similar demographics. The cohort of patients studied here provides adequate statistical 
power and also contains information on other time-varying covariates to adjust for possible 
confounders. We adjusted for a large set of factors that could have differed at the baseline 
through a robust PS-matching protocol. This is crucial since the decision to have bariatric 
surgery in routine clinical practice is often based on multiple factors, not confided to UK NICE 
guidelines. Nevertheless, some residual confounding in our study could persists due to our 
inability to measure and adjust for the dosage of the insulin therapy as well as the reliability 
of diabetes duration due to the ongoing issue of identifying incident versus prevalent 
diabetes. Also, the classification of exposure into two broad types of bariatric surgery could 
have possibly masked the effects of individual types of bariatric surgery and could have driven 
our study away or closer to the null hypothesis. Nonetheless, previous high profile studies on 
cardiovascular benefits of bariatric surgery have not looked at individual types of surgery.  
 
In summary, this study suggests that bariatric surgery in morbidly obese patients with insulin-
treated T2D is associated with a significant reduction in a non-fatal CHD and PAD events, as 
well as significant reduction in weight, HbA1c and insulin independence compared with 
matched control. The mechanism for this cardio-protective effects remained speculative but 
further study is required to confirm this observation. 
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Table 1. Baseline characteristics 
 Cohort  
Full population  
[N = 11,125] 
  Propensity matched  
[N = 710] 
  
 
Baseline variable 
Bariatric 
[n = 155] 
Non-bariatric 
[n = 10,970] 
 
Std. diff* 
Bariatric 
[n = 131] 
Non-bariatric 
[n = 579] 
 
Std. diff† 
Demographics       
Age (yrs), mean (SD) 50.01 (11.1) 57.71 (13.3) -0.694 50.74 (11.0) 51.96 (12.8) -0.110 
Gender, no (%) 
Female 89 (57.4) 5068 (46.2) 0.224 73 (55.4) 351 (60.6) -0.107 
Townsend deprivation, % 
Least deprived 14.0 21.7 -0.204 15.7 17.3 -0.044 
Less 24.3 20.7 0.086 24.0 18.1 0.145 
Average 17.6 21.4 -0.094 16.5 20.2 -0.094 
More 20.6 20.9 -0.008 21.5 27.7 -0.144 
Most deprived 23.5 15.3 0.209 22.3 16.8 0.14 
 
Type 2 diabetes (yrs) , mean (SD) 
Diabetes duration 14.15 (7.7) 15.12 (8.4) -0.125 13.97 (7.8) 14.89 (7.6) -0.117 
Insulin duration 7.36 (4.9) 8.01 (5.5) -0.130 7.3 (4.8) 8.68 (5.5) -0.287 
Clinical parameters, mean (SD) 
Weight (kg) 127.3 (30.3) 90.79 (20.6) 1.204 123.22 (28.3) 114.88 (24.5) 0.294 
Height (m) 1.7 (0.1) 1.68 (0.1) 0.201 1.7 (0.1) 1.69 (0.1) 0.102 
BMI (kg/m2) 43.87 (10.0) 32.37 (7.5) 1.150 42.77 (9.6) 40.6 (9.0) 0.226 
HbA1c (mmol/mol) 72.34 (19.3) 70.03 (17.2) 0.119 72.41 (18.6) 70.91 (17.9) 0.080 
Fasting glucose (mmol/L) 9.83 (4.3) 9.93 (3.9) -0.023 9.84 (4.3) 9.82 (3.9) 0.004 
Blood glucose (mmol/L) 12.22 (8.8) 11.69 (5.3) 0.071 12.04 (9.1) 11.92 (5.3) 0.016 
SBP (mmHg) 134.64 (14.6) 138.89 (16.5) -0.271 135.06 (14.5) 136.4 (16.0) -0.088 
DBP (mmHg) 78.66 (8.4) 78.94 (9.6) -0.031 79.3 (8.5) 78.77 (9.3) 0.058 
Albumin (g/dL) 3.96 (0.4) 4.15 (0.5) -0.368 3.96 (0.4) 3.96 (0.4) -0.005 
Alkaline Phosphatase (IU/L) 98.31 (47.1) 91.62 (43.0) 0.146 98.79 (48.8) 96.88 (51.5) 0.038 
Serum creatinine (µmol/L) 91.74 (78.4) 92.68 (52.6) -0.014 92.29 (84.0) 88.17 (57.7) 0.056 
C-reactive protein (mg/L) 10.02 (11.4) 14.23 (25.9) -0.208 10.15 (11.7) 10.07 (16.3) 0.006 
Globulin serum (g/L) 30.98 (5.4) 29.93 (4.6) 0.206 30.87 (5.3) 30.73 (4.8) 0.027 
Packed Cell Volume (L/L) 0.39 (0.04) 0.4 (0.05) -0.142 0.39 (0.04) 0.39 (0.06) 0.003 
Platelets count (109/L) 252.88 (99.4) 233.21 
(101.2) 
0.197 250.29 
(100.3) 
243.03 
(111.5) 
0.069 
Triglyceride (mmol/L) 2.33 (1.5) 2.03 (1.3) 0.2 2.34 (1.6) 2.26 (1.4) 0.049 
Total cholesterol (mmol/L) 4.47 (1.2) 4.49 (1.1) -0.019 4.52 (1.2) 4.52 (1.2) 0.002 
Low density lipoprotein 
(mmol/L) 
2.39 (0.9) 2.39 (0.9) 0.001 2.39 (0.9) 2.44 (1.0) -0.05 
High density lipoprotein 
(mmol/L) 
1.07 (0.3) 1.22 (0.4) -0.439 1.07 (0.3) 1.1 (0.3) -0.091 
Alcohol status, % 
Unknown 3.7 3.1 0.03 3.3 3.0 0.017 
Ex-drinker 11.8 7.0 0.162 11.6 11.5 0.003 
Never 33.1 31.3 0.039 33.1 33.1 -0.002 
Current 51.5 58.5 -0.143 52.1 52.4 -0.006 
 18 
 
Smoking status, % 
Ex-smoker 33.1 37.1 -0.085 31.4 36.9 -0.116 
Never 52.9 49.7 0.064 52.9 52.2 0.015 
Current 14.0 13.1 0.025 15.7 10.9 0.141 
Comorbidities, % 
AMI 24.3 20.3 0.095 23.1 20.2 0.073 
Stroke 11.0 12.9 -0.059 12.4 7.7 0.156 
CHD 77.9 75.6 0.055 78.5 72.9 0.132 
HF 18.4 17.8 0.016 17.4 18.5 -0.029 
PAD 18.4 14.6 0.101 18.2 11.3 0.195 
Diabetes duration is time from first diagnosis of diabetes to date of intensification with insulin drug (index date). 
* Standardised differences are the absolute difference in means or percentages divided by the SD of the treated group. 
Resulting standardised difference after 1:6 matching based on average treatment effect on treated propensity score 
technique and robust variance estimation. 
† Mean of standardized difference after matching (0.081), i.e. at 8% difference measured between the matched groups.  
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Table 2. Non-fatal cardiovascular events, crude incidence rates and hazard ratios of events in the 
matched groups. 
 Non-bariatric (N = 579) Bariatric (N = 131) 
AMI   
No of events/person-years 95/1084 13/153 
Absolute ratesa (95% CI) 87.6 (71.6–107.1) 84.9 (49.0–146.2) 
HRb (95% CI) 1 (reference) 1.03 (0.57–1.86) 
aHRc (95% CI) 1 (reference) 0.98 (0.54–1.77) 
   
Stroke   
No of events/person-years 40/547 8/137 
Absolute rates (95% CI) 73.0 (53.5–99.6) 58.2 (29.1–116.4) 
HR (95% CI) 1 (reference) 0.77 (0.34–1.72) 
aHR (95% CI) 1 (reference) 0.87 (0.36–2.10) 
   
CHD   
No of events/person-years 259/4446 18/840 
Absolute rates (95% CI) 58.2 (51.6–65.8) 21.4 (13.5–34.0) 
HR (95% CI) 1 (reference) 0.31 (0.19–0.52) 
aHR (95% CI) 1 (reference) 0.29 (0.16–0.52) 
   
HF   
No of events/person-years 91/1327 13/205 
Absolute rates (95% CI) 68.6 (55.8–84.2) 63 (36.9–109.5) 
HR (95% CI) 1 (reference) 0.81 (0.44–1.49) 
aHR (95% CI) 1 (reference) 0.89 (0.47–1.70) 
   
PAD   
No of events/person-years 53/718 6/231 
Absolute rates (95% CI) 73.9 (56.4–96.7) 25.9 (11.6–57.6) 
HR (95% CI) 1 (reference) 0.27 (0.09–0.74) 
aHR (95% CI) 1 (reference) 0.31 (0.11–0.89) 
a Absolute rate at 1000 person-years. 
b HR (unadjusted hazard ratio)  
c aHR (adjusted hazard ration). Adjusted for age, diabetes duration, oral antidiabetic drug use, diuretics 
use, antihypertensive drug use, Townsend deprivation status, alcohol & smoking status and HbA1c level. 
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Figure 1. Cardiovascular Kaplan-Meier survival analysis plot for the matched cohort throughout 10 years of 
follow-up. 
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Abstract 
 
Aims: To compare non-fatal cardiovascular (CV) events and metabolic outcomes, among 
obese patients with insulin-treated type 2 diabetes who underwent bariatric surgery 
compared to a propensity matched non-bariatric cohort. 
Methods: A retrospective cohort study was conducted among 11,125 active patients with 
type 2 diabetes from The Health Improvement Network (THIN) database. Propensity score 
matching (1:6 ratio) was used to identify patients who underwent bariatric surgery (N=131) 
with a non-bariatric cohort (N=579).  Follow-up was undertaken for 10 years (9,686 person-
years) to compare differences in metabolic outcomes and CV risk events that included: 
Acute Myocardial Infarction (AMI), stroke, Coronary Heart Disease (CHD), Heart Failure (HF) 
and Peripheral Artery Disease (PAD). Cox proportional regression was used to compute the 
outcomes between groups. 
Results: Mean age was 52±13 years (60% female); baseline weight and BMI were 116±25kg 
and 41±9kg/m2, respectively. Significant reductions in weight and BMI were observed in 
bariatric and non-bariatric cohorts during 10 years of follow-up. Bariatric surgery had a 
significant cardio-protective effect by reducing the risk of non-fatal CHD (adjusted hazard 
ratio [aHR]: 0.29, 95%CI:0.16–0.52, p<0.001) and PAD events (aHR: 0.31; 95%CI:0.11–0.89; 
p=0.03). However, surgery had no significant effect on AMI (aHR:0.98, p=0.95), stroke 
(HR:0.87, p=0.76) and HF (HR:0.89, p=0.73) risks. Bariatric surgery had favourable effects on 
insulin-independence, HbA1c and BP. 
Conclusion: Among obese insulin-treated patients with type 2 diabetes, bariatric surgery is 
associated with significant reductions in non-fatal CHD and PAD events, lower body weight, 
BP, and a greater likelihood of insulin independence during 10 years of follow-up. 
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What is already known about this subject? 
- Obesity and type 2 diabetes are associated with high risk of cardiovascular events 
- Obesity is causally associated with peripheral artery disease 
- Insulin –treated type 2 diabetes is associated with additional excess risk of 
cardiovascular events 
- Bariatric surgery in people with or without diabetes reduces cardiovascular events 
 
What does this study add? 
- This study focuses on insulin treated type 2 diabetes – recently recognised to be 
associated with higher risks of cardiovascular events 
- Among insulin treated type 2 diabetes, bariatric surgery is associated with significant 
reduction in non-fatal coronary heart disease and peripheral artery disease 
- Among insulin treated type 2 diabetes, bariatric surgery is associated with significant 
reduction and maintenance of weight loss, significant reduction in HbA1c, with 
relapse of HbA1c levels after 6 years of follow up and significant increase of insulin 
independence 
-  
How might this impact on clinical practice? 
- Bariatric surgery should be considered as a genuine therapeutic option for the 
management of obese insulin treated type 2 diabetes to reduce coronary heart 
disease, peripheral artery disease events, reduce HbA1c levels and potentially 
reduce long-term risk of microvascular complications of diabetes as well as inducing 
insulin indepence. 
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Background 
Obesity and Type 2 diabetes (T2D) are major global health problems that are intrinsically 
linked with adverse cardiovascular (CV) outcomes1,2. Obesity-associated coronary artery 
disease and myocardial dysfunction have been shown to be a direct consequence of excess 
dysfunctional adipose tissue, driven by increased pro-inflammatory state, insulin resistance, 
endothelial dysfunction and the development of myocardial hypertrophy3. Consequently, 
weight loss by any means has been shown to improve CV outcomes4. Although diet and 
exercise play a crucial role in obesity management, lifestyle alone may not achieve durable 
weight loss in the majority of patients5. Bariatric surgery therefore has emerged as the most 
effective and durable strategy for long-term weight loss in morbidly obese individuals6. The 
two most commonly performed bariatric surgical procedures are the Roux-en-Y gastric bypass 
(RYGB) and sleeve gastrectomy (SG). Indeed, previous studies have shown beneficial effects 
of these bariatric surgical procedures on CV outcomes7-9.  
 
Many patients with T2D will require insulin treatment to manage hyperglycaemia, to reduce 
the risk of long-term vascular complications10. However, insulin therapy is known to induce 
~4-9 kg weight gain in the first year of treatment, while escalation of insulin treatment doses 
are associated with greater weight gain11 and excess CV risk12.  Furthermore, evidence from 
randomized controlled trial and observational studies have implicated insulin therapy in 
patients with T2D with increased CV risk and mortality13-16, possibly due to weight gain, 
recurrent hypoglycaemia and iatrogenic hyperinsulinemia17,18. Thus, a cohort of insulin-
treated patients with T2D, represent a complex heterogenous, challenging group of patients, 
many of whom have significant comorbidities and high CV disease risk. No studies have 
assessed the effect bariatric surgery on cardiovascular outcomes among insulin-treated 
patients with T2D in routine clinical care. 
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Methods 
Study design, data sources and study population 
This was a retrospective cohort study that used The Health Improvement Network (THIN), an 
anonymised health care records derived from over 600 UK general practices, containing 
details on demographics, lifestyle characteristics, major medical and surgical conditions, drug 
utilisation, and health outcomes of over 17 million patients, 3.1 million of which are active 
patients19. Our dataset contains all adult patients (age >18 years) with T2D and have been 
prescribed with any form of insulin therapy up to September 2017 (N=11,125). Patients’ index 
date was either the day of bariatric surgery (RYGB or SG) or, in case they have not received 
bariatric surgery, first intensification of insulin therapy. We excluded patients with type 1 
diabetes or non- insulin-treated T2D. Ethics approval was provided by the NHS South East 
Multi-centre Research Ethics Committee (MREC). 
 
Exposure and outcomes 
Exposure of interest is bariatric surgery (RYGB or SG). Patients were censored throughout 10 
years of follow-up – following the development of primary outcome, transferred out, loss to 
follow-up or at the end of the study. Primary outcome was patients’ survivability against non-
fatal CV events with further stratification to include CV events into divisions of time to the risk 
of Acute Myocardial Infarction (AMI), stroke, Coronary Heart Disease (CHD), Heart Failure (HF) 
and Peripheral Artery Disease (PAD). Secondary outcomes included health covariates such as 
body weight, calculated BMI, HbA1c, total cholesterol, systolic/diastolic blood pressure and 
insulin independence.  
 
Covariates and follow-up strategy 
We followed-up the treatment group whom underwent bariatric surgery and compared with 
their propensity-matched (PS) matched non-bariatric surgery from their first insulin 
prescription date up to the endpoint of 10-year of follow-up. Patients with CV events prior to 
the designated baseline point were excluded from the primary survival estimation on each 
stratified CV element. Baseline clinical parameters (average values from multiple entries) 
were measured at the same time window according to patient’s treatment category, i.e. 90 
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days up to one day before the surgery date or first intensification of insulin therapy. 
Covariates were, then, recalculated at 6-month, and at each year point up to 10 years of 
follow-up; with 90 days window on every concurring point of time. 
 
Statistical analysis 
Primary analysis was time to the risk of stratified non-fatal CV events that included AMI, 
stroke, CHD, HF and PAD in a PS-matched groups. The PS model was estimated by using 
logistic regression model to adjust for baseline characteristics, thus, minimising allocation bias 
between groups. The balance assessment was made between bariatric (treated) and non-
bariatric (untreated) groups by measuring standardised differences before and after the 
matching procedure. The mean form continuous covariates and proportion of categorical 
variables between groups were examined and summarised. Each treatment subject was 
matched to six reference subjects at the nearest distance measured by the estimated PS, 
based on the estimated treatment probabilities20. We employed caliper width=0.05 of the 
standard deviation of the logit of the PS to minimise distance within matched sets which may 
improve match quality but would limit excessive number of matched subjects21. A caliper 
width of <0.2 has been shown to result in optimal estimation compared to higher choices of 
caliper use22. PS was included in all Cox proportional hazards regression modelling as it was 
considered a prognostic covariate. Stratified log-rank test, with Kaplan-Meier survival curves 
respectively was used to compare the equality between the PS-matched groups. The absolute 
reduction in the probability of an event occurring within 10-year follow-up was calculated. 
Marginal hazard ratios were estimated to quantify the adjusted hazard of an event occurred 
in the bariatric group compared to the matched non-bariatric group. Proportional hazards 
assumptions were confirmed through Schoenfeld residuals test. Point estimates with 95% 
Confidence Intervals (CIs) at the conventional statistical significance level of 0.05 were used 
in the regression models. The proportional hazards assumption was examined by comparing 
the cumulative hazard plots grouped on exposure; no violations were observed. 
 
Missing data among covariates were managed through multiple imputations using the 
predictive means matching for continuous covariates with accounting to exposure (i.e. 
bariatric), age, gender, diabetes duration, Townsend deprivation status, marital status, 
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smoking and alcohol use23. To test the adequacy of our multiple imputation approach in 
addressing the impact of some missing data, we conducted a sensitivity analysis wherein the 
primary endpoints in the imputed dataset and were compared with the dataset with missing 
values and found to be similar, thereby affirming the robustness of the imputation method 
employed before PS matching procedure was performed24.  
 
We used Student’s t-test to estimate the mean changes in continuous variables (e.g. body 
weight & HbA1c) in both PS matched groups throughout 10-year of follow-up compared to 
their baseline measurements; and Pearson X2 to test on the likelihood of being off insulin at 
5 and 10 years from the baseline. Statistical significance was put at a p level of 0.05. To avoid 
the probability of type II error, the study was powered to 0.8 and the matched sample size of 
710 was found to detect a true difference of less than 0.1 between the two groups at 5% 
significance level. The study fulfilled the STROBE criteria for reporting observational studies. 
Throughout, we used SAS Software version 9.4 in the initial dataset management (SAS 
Institute, Cary, NC); Stata Statistical Software version 15.1 in all carried analysis (StataCorp., 
College Station, TX); and GraphPad/Prism version 8.0 for visualisation (La Jolla, CA).  
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Results 
Patients’ characteristics and total follow-up 
From 11,125 patients with insulin-treated T2D, we identified 155 patients who have had 
bariatric surgical operation. The PS matching procedure allowed 131 bariatric patients to be 
matched with up to six control subjects. This yielded a total number of 710 PS-matched 
participants. The median treatment duration was 10.07 years (interquartile range (IQR): 6.11–
14.31 years). The median follow-up was 8.42 years (IQR: 2.92–14.58 years) representing a 
total follow-up period of 9,686 person-years.  
 
In the matched cohort, the overall mean of age was 51.7 (SD 12.5) years; 59.6% were females. 
The mean body weight, BMI and HbA1c level were 115.7 (SD 25.4) kg, 40.7 (SD 9.2) kg/m2 and 
71.2 (SD 18.1) mmol/mol, respectively. The baseline characteristics in both bariatric and non-
bariatric groups were compared between the full and matched cohort with their standardised 
differences shown in Table 1. 
 
Cardiovascular event rates 
The probability of survival for non-fatal CHD was significantly different between matched 
bariatric and non-bariatric groups at 1-year (98.0% vs 89.6%), 5-year (92.2% vs 67.6%) and 10-
year (88.2% vs 51.6%) of follow-up (log-rank test p < 0.001) (Fig. 1c). A total of 277 (18 vs 259) 
events were reported with a crude event rate of 52.4 (21.4 vs 58.2) per 1000 person-years 
(95% CI 46.6–58.9). The probability of survival for non-fatal PAD was also significantly 
different at 5-year (90.5% vs 78.8%) and 10-year (84.0% vs 53.1%) of follow-up (log-rank test 
p = 0.007) (Fig. 1e). A total of 59 (6 vs 53) events were observed with a crude event rate of 
62.1 (25.9 vs 73.8) per 1000 person-year (95% CI 48.1–80.2). The probabilities of survival for 
non-fatal AMI, stroke and HF were with little or no statistical significance between the 
matched groups throughout 10 years of follow-up (log-rank test p > 0.5) (Fig. 1a, 1b & 1d). 
Table 2 shows a summary of the events for each of the stratified CV components with 
absolute event rates.  
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Bariatric surgery was protective against all analysed CV elements in the matched cohort. The 
risk of non-fatal CHD and PAD in the bariatric group were significantly lower (by 71% & 69%, 
respectively) compared to the matched non-bariatric group (CHD aHR: 0.29, 95%CI 0.16–0.52, 
p < 0.001; PAD aHR: 0.31, 95%CI 0.11–0.89, p = 0.03) adjusted for age, HbA1c level, diabetes 
duration, oral antidiabetic drug use, diuretics use, antihypertensive drug use, Townsend 
deprivation status, alcohol use and smoking status. Despite protective tendency against non-
fatal AMI, stroke and HF, none of which was found with statistical significance (AMI aHR: 0.98, 
95%CI 0.54–1.77, p = 0.94; stroke aHR: 0.87, 95%CI 0.36–2.10, p = 0.75; HF aHR: 0.89, 95%CI 
0.47–1.70, p = 0.73) (Table 2).  
 
Changes in metabolic outcomes 
Significant reductions in the matched cohort (i.e. p < 0.001) favouring the bariatric group vs 
non-bariatric was observed in terms of body weight and BMI throughout all 10 years of follow-
up compared to baseline. Body weight and BMI for bariatric vs non-bariatric were: at 1-year 
point (97.5±24.2 vs 109.8±18.6 kg; 34.2±9.0 vs 38.8±7.4 kg/m2, respectively), at 5-year point 
(98.9±23.3 vs 107.1±18.2 kg; 34.8±9.2 vs 37.8±7.3 kg/m2, respectively), and at 10-year point 
(94.1±20.1 vs 107.6±17.3 kg; 32.9±7.7 vs 38.0±7.1 kg/m2, respectively) of follow-up (Fig. 2a & 
2b). The reduction in HbA1c was statistically significant up to six years of follow-up. At the 
first year the level of HbA1c in the bariatric vs non-bariatric (60.3±18.2 vs 72.0±17.9 
mmol/mol), at 3-year point (66.1±16.8 vs 71.3±17.8 mmol/mol) and at 6-year point 
(68.1±16.9 vs 72.8±18.8 mmol/mol). No statistical difference was observed beyond the 
seventh year in the HbA1c level between the matched groups (Fig. 2c). Total cholesterol was 
significantly reduced during the first six months of follow-up (4.12±0.99 vs 4.50±1.14 mmol/L, 
p = 0.008) (Fig. 2d). Blood pressure was also significantly reduced early following the bariatric 
surgery. The systolic blood pressure at 6-month point (130±18 vs 137±16 mmHg, p < 0.001) 
and at 1-year point (133±17 vs 137±15 mmHg, p = 0.07) (Fig. 2e). The diastolic blood pressure 
was significantly reduced in the bariatric vs non-bariatric (p < 0.05) up to two years of follow-
up (6-month: 76±10 vs 79±9; 1-year: 77±9 vs 79±9; 2-year: 76±10 vs 79±10 mmHg) (Fig. 2f). 
Figure 2 represents reduction in the matched cohort of the analysed outcome variables 
during 10 years of follow-up in comparison to their baseline measurements with 95% 
confidence intervals.  
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The analysis of the matched groups also revealed that, at one year of follow-up, 6.4% of whom 
underwent bariatric surgery were insulin independent compared to 7.9% non-bariatric with 
little or no statistical significance of a difference (X2=0.35, p = 0.55). At three years, 31.2% of 
bariatric patients were independent from insulin use compared to 17.6% non-bariatric 
(X2=10.59, p = 0.001). At six years, 41.5% of bariatric patients were independent from using 
insulin compared to 22.2% non-bariatric (X2=11.47, p = 0.001). At 10 years, 77.5% of bariatric 
patients were independent from using insulin compared to 33.7% non-bariatric (X2=28.71, p 
< 0.0001).   
 
Discussion  
This study showed that, among morbidly obese patients with insulin-treated T2D in routine 
clinical practice, bariatric surgery was associated with a significant 71% risk reduction in non-
fatal CHD and 69% reduction in PAD events, as well as significant reductions in weight, HbA1c, 
insulin independence and blood pressure. However, no significant reductions was observed 
with AMI, stroke and heart failure.    
 
Our findings were similar in pattern with previous observational studies on bariatric surgery 
with regards to cardiovascular and metabolic benefits7-9. Our study however focuses on 
patients with Insulin-treated T2D – known to be associated with higher risks of cardiovascular 
events13-16. Indeed, a previous study have shown that while bariatric surgery reduces 
cardiovascular events and mortality, the mortality risk in people with diabetes after bariatric 
surgery remains 35% higher than that of the general population.25  Our study therefore extends 
evidence of cardiovascular benefit of bariatric surgery in this patient cohort whose residual 
CV risk are likely to be higher.   Interestingly, a previous study in patients with diabetes reported a 
reduction in myocardial infarction but no effect was observed on stroke incidence8.  However, a 
factor–treatment interaction analysis showed that the effect of bariatric surgery on AMI was 
greater in participants with higher total cholesterol and triglyceride levels, implying that those 
with dyslipidemia were the ones who are likely to gain the most benefit. Since our PS-matched 
cohort have optimal mean LDL-cholesterol and triglyceride levels (~2.4 and 2.3 mmol/L), 
respectively due to high use of statin therapy, this may explain the lack of significant reduction 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 11 
 
of AMI in our cohort while highlighting the importance of statin therapy in this patient cohort.  
Our observation of significant reduction in PAD events within this patient cohort is novel and 
have major clinical significant. A recent study have concluded that obesity is causally 
associated with PAD after controlling for potential confounders like hypertension, 
dyslipidemia and hyperglycemia26.  
 
Insulin therapy is known to induce weight gain11. Our data showed a major reduction in 
weight following bariatric surgery, which persisted at 10 years of follow up. While greater 
significant reduction in weight following bariatric surgery compared with control is 
anticipated, it is interesting to note that weight loss was also observed in our PS-matched 
control cohort. This is likely due to concurrent use of GLP-1 analogue in our patient cohort. 
Evidence of weight loss with GLP-1 as adjunct to insulin treatment has been shown in 
randomized controlled trials.27,28  In addition, we have also reported significant weight loss 
after 12 months of adding a GLP-1 to insulin therapy in routine clinical practice29. Of note, 
weight loss was not observed in our non- PS-matched control cohort, indicating robust PS 
matching protocol used in this study analysis (Supplement). The addition of GLP-1 therapy, in 
combination with use of other novel weight loss antidiabetic regimens like sodium glucose 
co-tranporter-2 (SGLT-2) inhibitor, as well as significant calorie restriction may also explain 
the smaller but appreciable percentage of patients who were insulin independence in the PS-
matched control cohort, compared with those who underwent bariatric surgery. 
Interestingly, in contrast to the observed weight loss which persisted over 10 years of follow-
up, the reduction in HbA1c was statistically significance only up to six years of follow-up post-
surgery, with a rise in HbA1c during further follow-up. Previous studies comparing bariatric 
surgery outcomes with medical/lifestyle intervention have mainly reported HbA1c reduction 
up to five years post surgery30-32, albeit in patients with T2D irrespective of treatment 
regimen. The discordance between long-term weight and HbA1c outcomes suggested that 
the observed relapse in HbA1c level was independent of weight regain.  Nonetheless, any 
beneficial effects of bariatric surgery on weight, HbA1c reduction and insulin independence 
will have significant impact on the long-term risk of vascular complications of diabetes and 
will likely confer cost savings to the UK National Health Service in the long-term.   
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The main strength of our study derives from the inclusion of a relatively large cohort of insulin-
treated T2D in a real-world population which can be generalized to the UK or similar 
population. This implies that our findings will be generalizable to various population with 
similar demographics. The cohort of patients studied here provides adequate statistical 
power and also contains information on other time-varying covariates to adjust for possible 
confounders. We adjusted for a large set of factors that could have differed at the baseline 
through a robust PS-matching protocol. This is crucial since the decision to have bariatric 
surgery in routine clinical practice is often based on multiple factors, not confided to UK NICE 
guidelines. Nevertheless, some residual confounding in our study could persists due to our 
inability to measure and adjust for the dosage of the insulin therapy as well as the reliability 
of diabetes duration due to the ongoing issue of identifying incident versus prevalent 
diabetes. Also, the classification of exposure into two broad types of bariatric surgery could 
have possibly masked the effects of individual types of bariatric surgery and could have driven 
our study away or closer to the null hypothesis. Nonetheless, previous high profile studies on 
cardiovascular benefits of bariatric surgery have not looked at individual types of surgery.  
 
In summary, this study suggests that bariatric surgery in morbidly obese patients with insulin-
treated T2D is associated with a significant reduction in a non-fatal CHD and PAD events, as 
well as significant reduction in weight, HbA1c and insulin independence compared with 
matched control. The mechanism for this cardio-protective effects remained speculative but 
further study is required to confirm this observation. 
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Table 1. Baseline characteristics 
 Cohort  
Full population  
[N = 11,125] 
  Propensity matched  
[N = 710] 
  
 
Baseline variable 
Bariatric 
[n = 155] 
Non-bariatric 
[n = 10,970] 
 
Std. diff* 
Bariatric 
[n = 131] 
Non-bariatric 
[n = 579] 
 
Std. diff† 
Demographics       
Age (yrs), mean (SD) 50.01 (11.1) 57.71 (13.3) -0.694 50.74 (11.0) 51.96 (12.8) -0.110 
Gender, no (%) 
Female 89 (57.4) 5068 (46.2) 0.224 73 (55.4) 351 (60.6) -0.107 
Townsend deprivation, % 
Least deprived 14.0 21.7 -0.204 15.7 17.3 -0.044 
Less 24.3 20.7 0.086 24.0 18.1 0.145 
Average 17.6 21.4 -0.094 16.5 20.2 -0.094 
More 20.6 20.9 -0.008 21.5 27.7 -0.144 
Most deprived 23.5 15.3 0.209 22.3 16.8 0.14 
 
Type 2 diabetes (yrs) , mean (SD) 
Diabetes duration 14.15 (7.7) 15.12 (8.4) -0.125 13.97 (7.8) 14.89 (7.6) -0.117 
Insulin duration 7.36 (4.9) 8.01 (5.5) -0.130 7.3 (4.8) 8.68 (5.5) -0.287 
Clinical parameters, mean (SD) 
Weight (kg) 127.3 (30.3) 90.79 (20.6) 1.204 123.22 (28.3) 114.88 (24.5) 0.294 
Height (m) 1.7 (0.1) 1.68 (0.1) 0.201 1.7 (0.1) 1.69 (0.1) 0.102 
BMI (kg/m2) 43.87 (10.0) 32.37 (7.5) 1.150 42.77 (9.6) 40.6 (9.0) 0.226 
HbA1c (mmol/mol) 72.34 (19.3) 70.03 (17.2) 0.119 72.41 (18.6) 70.91 (17.9) 0.080 
Fasting glucose (mmol/L) 9.83 (4.3) 9.93 (3.9) -0.023 9.84 (4.3) 9.82 (3.9) 0.004 
Blood glucose (mmol/L) 12.22 (8.8) 11.69 (5.3) 0.071 12.04 (9.1) 11.92 (5.3) 0.016 
SBP (mmHg) 134.64 (14.6) 138.89 (16.5) -0.271 135.06 (14.5) 136.4 (16.0) -0.088 
DBP (mmHg) 78.66 (8.4) 78.94 (9.6) -0.031 79.3 (8.5) 78.77 (9.3) 0.058 
Albumin (g/dL) 3.96 (0.4) 4.15 (0.5) -0.368 3.96 (0.4) 3.96 (0.4) -0.005 
Alkaline Phosphatase (IU/L) 98.31 (47.1) 91.62 (43.0) 0.146 98.79 (48.8) 96.88 (51.5) 0.038 
Serum creatinine (µmol/L) 91.74 (78.4) 92.68 (52.6) -0.014 92.29 (84.0) 88.17 (57.7) 0.056 
C-reactive protein (mg/L) 10.02 (11.4) 14.23 (25.9) -0.208 10.15 (11.7) 10.07 (16.3) 0.006 
Globulin serum (g/L) 30.98 (5.4) 29.93 (4.6) 0.206 30.87 (5.3) 30.73 (4.8) 0.027 
Packed Cell Volume (L/L) 0.39 (0.04) 0.4 (0.05) -0.142 0.39 (0.04) 0.39 (0.06) 0.003 
Platelets count (109/L) 252.88 (99.4) 233.21 
(101.2) 
0.197 250.29 
(100.3) 
243.03 
(111.5) 
0.069 
Triglyceride (mmol/L) 2.33 (1.5) 2.03 (1.3) 0.2 2.34 (1.6) 2.26 (1.4) 0.049 
Total cholesterol (mmol/L) 4.47 (1.2) 4.49 (1.1) -0.019 4.52 (1.2) 4.52 (1.2) 0.002 
Low density lipoprotein 
(mmol/L) 
2.39 (0.9) 2.39 (0.9) 0.001 2.39 (0.9) 2.44 (1.0) -0.05 
High density lipoprotein 
(mmol/L) 
1.07 (0.3) 1.22 (0.4) -0.439 1.07 (0.3) 1.1 (0.3) -0.091 
Alcohol status, % 
Unknown 3.7 3.1 0.03 3.3 3.0 0.017 
Ex-drinker 11.8 7.0 0.162 11.6 11.5 0.003 
Never 33.1 31.3 0.039 33.1 33.1 -0.002 
Current 51.5 58.5 -0.143 52.1 52.4 -0.006 
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Smoking status, % 
Ex-smoker 33.1 37.1 -0.085 31.4 36.9 -0.116 
Never 52.9 49.7 0.064 52.9 52.2 0.015 
Current 14.0 13.1 0.025 15.7 10.9 0.141 
Comorbidities, % 
AMI 24.3 20.3 0.095 23.1 20.2 0.073 
Stroke 11.0 12.9 -0.059 12.4 7.7 0.156 
CHD 77.9 75.6 0.055 78.5 72.9 0.132 
HF 18.4 17.8 0.016 17.4 18.5 -0.029 
PAD 18.4 14.6 0.101 18.2 11.3 0.195 
Diabetes duration is time from first diagnosis of diabetes to date of intensification with insulin drug (index date). 
* Standardised differences are the absolute difference in means or percentages divided by the SD of the treated group. 
Resulting standardised difference after 1:6 matching based on average treatment effect on treated propensity score 
technique and robust variance estimation. 
† Mean of standardized difference after matching (0.081), i.e. at 8% difference measured between the matched groups.  
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Table 2. Non-fatal cardiovascular events, crude incidence rates and hazard ratios of events in the 
matched groups. 
 Non-bariatric (N = 579) Bariatric (N = 131) 
AMI   
No of events/person-years 95/1084 13/153 
Absolute ratesa (95% CI) 87.6 (71.6–107.1) 84.9 (49.0–146.2) 
HRb (95% CI) 1 (reference) 1.03 (0.57–1.86) 
aHRc (95% CI) 1 (reference) 0.98 (0.54–1.77) 
   
Stroke   
No of events/person-years 40/547 8/137 
Absolute rates (95% CI) 73.0 (53.5–99.6) 58.2 (29.1–116.4) 
HR (95% CI) 1 (reference) 0.77 (0.34–1.72) 
aHR (95% CI) 1 (reference) 0.87 (0.36–2.10) 
   
CHD   
No of events/person-years 259/4446 18/840 
Absolute rates (95% CI) 58.2 (51.6–65.8) 21.4 (13.5–34.0) 
HR (95% CI) 1 (reference) 0.31 (0.19–0.52) 
aHR (95% CI) 1 (reference) 0.29 (0.16–0.52) 
   
HF   
No of events/person-years 91/1327 13/205 
Absolute rates (95% CI) 68.6 (55.8–84.2) 63 (36.9–109.5) 
HR (95% CI) 1 (reference) 0.81 (0.44–1.49) 
aHR (95% CI) 1 (reference) 0.89 (0.47–1.70) 
   
PAD   
No of events/person-years 53/718 6/231 
Absolute rates (95% CI) 73.9 (56.4–96.7) 25.9 (11.6–57.6) 
HR (95% CI) 1 (reference) 0.27 (0.09–0.74) 
aHR (95% CI) 1 (reference) 0.31 (0.11–0.89) 
a Absolute rate at 1000 person-years. 
b HR (unadjusted hazard ratio)  
c aHR (adjusted hazard ration). Adjusted for age, diabetes duration, oral antidiabetic drug use, diuretics 
use, antihypertensive drug use, Townsend deprivation status, alcohol & smoking status and HbA1c level. 
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Figure 1. Cardiovascular Kaplan-Meier survival analysis plot for the matched cohort throughout 10 years of 
follow-up. 
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 1 
STROBE Statement—checklist of items that should be included in reports of observational studies 
 
 Item 
No Recommendation 
Page 
number 
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the 
abstract 
1 
(b) Provide in the abstract an informative and balanced summary of what was 
done and what was found 
2 
Introduction  
Background/rationale 2 Explain the scientific background and rationale for the investigation being 
reported 
4 
Objectives 3 State specific objectives, including any prespecified hypotheses 4 
Methods  
Study design 4 Present key elements of study design early in the paper 5 
Setting 5 Describe the setting, locations, and relevant dates, including periods of 
recruitment, exposure, follow-up, and data collection 
5,6 
Participants 6 (a) Cohort study—Give the eligibility criteria, and the sources and methods of 
selection of participants. Describe methods of follow-up 
Case-control study—Give the eligibility criteria, and the sources and methods 
of case ascertainment and control selection. Give the rationale for the choice of 
cases and controls 
Cross-sectional study—Give the eligibility criteria, and the sources and 
methods of selection of participants 
5,6 
 
(b) Cohort study—For matched studies, give matching criteria and number of 
exposed and unexposed 
Case-control study—For matched studies, give matching criteria and the 
number of controls per case 
6 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and 
effect modifiers. Give diagnostic criteria, if applicable 
6,7 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details of methods of 
assessment (measurement). Describe comparability of assessment methods if 
there is more than one group 
6,7 
Bias 9 Describe any efforts to address potential sources of bias 6,7 
Study size 10 Explain how the study size was arrived at 7 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, 
describe which groupings were chosen and why 
5-7 
Statistical methods 12 (a) Describe all statistical methods, including those used to control for 
confounding 
 6-7 
(b) Describe any methods used to examine subgroups and interactions 7 
(c) Explain how missing data were addressed 6-7 
(d) Cohort study—If applicable, explain how loss to follow-up was addressed 
Case-control study—If applicable, explain how matching of cases and controls 
was addressed 
Cross-sectional study—If applicable, describe analytical methods taking 
account of sampling strategy 
 
(e) Describe any sensitivity analyses  
Continued on next page  
Strobe checklist
 2 
Results  
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, 
examined for eligibility, confirmed eligible, included in the study, completing follow-up, 
and analysed 
8 
(b) Give reasons for non-participation at each stage  
(c) Consider use of a flow diagram  
Descriptive 
data 
14* (a) Give characteristics of study participants (eg demographic, clinical, social) and 
information on exposures and potential confounders 
8, 
Table 1 
(b) Indicate number of participants with missing data for each variable of interest  
(c) Cohort study—Summarise follow-up time (eg, average and total amount) 8 
Outcome data 15* Cohort study—Report numbers of outcome events or summary measures over time 8,9 
Table 2 
Case-control study—Report numbers in each exposure category, or summary measures of 
exposure 
 
Cross-sectional study—Report numbers of outcome events or summary measures  
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their 
precision (eg, 95% confidence interval). Make clear which confounders were adjusted for 
and why they were included 
8-10, 
Table 2 
(b) Report category boundaries when continuous variables were categorized  
(c) If relevant, consider translating estimates of relative risk into absolute risk for a 
meaningful time period 
 
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity 
analyses 
10 
Discussion  
Key results 18 Summarise key results with reference to study objectives 10 
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or 
imprecision. Discuss both direction and magnitude of any potential bias 
12 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, 
multiplicity of analyses, results from similar studies, and other relevant evidence 
11-12 
Generalisability 21 Discuss the generalisability (external validity) of the study results 12 
Other information  
Funding 22 Give the source of funding and the role of the funders for the present study and, if 
applicable, for the original study on which the present article is based 
NA 
 
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and 
unexposed groups in cohort and cross-sectional studies. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and 
published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely 
available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at 
http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is 
available at www.strobe-statement.org. 
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